Online first
Artykuł przeglądowy
Opublikowany online: 2024-05-17
Wyświetlenia strony
203
Wyświetlenia/pobrania artykułu
9
Potencjał terapeutyczny wybranych substancji psychoaktywnych — przegląd najnowszych badań
1, 1, 1, 2
, 2
, 2
DOI: 10.5603/psych.99558
Streszczenie
Terapie farmakologiczne wielu schorzeń psychiatrycznych nie spełniają oczekiwań pacjentów. Poszukiwane są nowe środki do leczenia m.in. depresji i zaburzeń lękowych. Naukowe zainteresowanie substancjami psychoaktywnymi wzrosło w ciągu ostatnich kilku dekad. Najnowsze badania dostarczają dowodów na to, że psychodeliki mogą znaleźć zastosowanie w leczeniu szeregu zaburzeń psychicznych. W niniejszym artykule opisano nowe badania przeprowadzone od 2019 r. nad najpopularniejszymi psychodelikami: LSD, MDMA, psylocybiny i THC. Analiza została rozszerzona o substancje mniej popularne w użytku rekreacyjnym i naukowym, takie jak 5-MeO-DMT, dekstrometorfan, DMT, ibogaina, ketamina i meskalina. Wydaje się, że opisane halucynogeny wykazują potencjał terapeutyczny w leczeniu uzależnień (nikotyna, alkohol i uzależnienie od substancji), depresji, lęku (w tym lęku współistniejącego w zaburzeniach ze spektrum autyzmu), PTSD, zaburzeń odżywiania i zespołu Tourette'a. Po opracowaniu odpowiednich protokołów, środki psychoaktywne mogą stać się elementem kompleksowej i skutecznej terapii.
Słowa kluczowe: środki psychoaktywneMDMALSDDXM5-MeO-DMTmeskalinaibogaina
Referencje
- Derakhshanian S, Zhou M, Rath A, et al. Role of ketamine in the treatment of psychiatric disorders. Health Psychol Res. 2021; 9(1): 25091.
- Król B, Szewczak B, Rozenek EB, et al. Therapeutic use of selected psychoactive substances. Psychiatria. 2019; 16(3): 154–62.
- Kargbo RB. Psilocybin therapeutic research: the present and future paradigm. ACS Med Chem Lett. 2020; 11(4): 399–402.
- Rodrigues AV, Almeida FJ, Vieira-Coelho MA. Dimethyltryptamine: endogenous role and therapeutic potential. J Psychoactive Drugs. 2019; 51(4): 299–310.
- Pic-Taylor A, da Motta LG, de Morais JA, et al. Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat. Behav Processes. 2015; 118: 102–110.
- D'Souza DC, Syed SA, Flynn LT, et al. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology. 2022; 47(10): 1854–1862.
- Dos Santos RG, Hallak JE. Ayahuasca, an ancient substance with traditional and contemporary use in neuropsychiatry and neuroscience. Epilepsy Behav. 2021; 121(Pt B): 106300.
- Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019; 49(4): 655–663.
- Uthaug MV, Mason NL, Toennes SW, et al. A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology (Berl). 2021; 238(7): 1899–1910.
- Libânio Osório Marta RF. Metabolism of lysergic acid diethylamide (LSD): an update. Drug Metab Rev. 2019; 51(3): 378–387.
- Family N, Maillet EL, Williams LTJ, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology (Berl). 2020; 237(3): 841–853.
- Moda-Sava RN, Murdock MH, Parekh PK, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019; 364(6436).
- Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012; 26(7): 994–1002.
- Holze F, Gasser P, Müller F, et al. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry. 2023; 93(3): 215–223.
- Davis AK, So S, Lancelotta R, et al. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse. 2019; 45(2): 161–169.
- El-Seedi HR, De Smet PA, Beck O, et al. Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J Ethnopharmacol. 2005; 101(1-3): 238–242.
- Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions. Curr Mol Pharmacol. 2019; 12(3): 184–194.
- Agin-Liebes G, Haas TF, Lancelotta R, et al. Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol Transl Sci. 2021; 4(2): 543–552.
- Lowe H, Toyang N, Steele B, et al. The therapeutic potential of psilocybin. Molecules. 2021; 26(10).
- Sarparast A, Thomas K, Malcolm B, et al. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology (Berl). 2022; 239(6): 1945–1976.
- Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018; 235(2): 399–408.
- Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022; 36(2): 151–158.
- MacCallum CA, Lo LA, Pistawka CA, et al. Therapeutic use of psilocybin: Practical considerations for dosing and administration. Front Psychiatry. 2022; 13: 1040217.
- van der Meer PB, Fuentes JJ, Kaptein AdA, et al. Therapeutic effect of psilocybin in addiction: a systematic review. Front Psychiatry. 2023; 14: 1134454.
- Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022; 79(10): 953–962.
- Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023; 29(8): 1947–1953.
- Shen HW, Jiang XL, Winter JC, et al. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab. 2010; 11(8): 659–666.
- Davis AK, Barsuglia JP, Lancelotta R, et al. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol. 2018; 32(7): 779–792.
- Uthaug MV, Lancelotta R, van Oorsouw K, et al. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology (Berl). 2019; 236(9): 2653–2666.
- Reckweg JT, van Leeuwen CJ, Henquet C, et al. A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Front Psychiatry. 2023; 14: 1133414.
- Barsuglia J, Davis AK, Palmer R, et al. Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. Front Psychol. 2018; 9: 2459.
- Kverno K. Dextromethorphan: from cough suppressant to antidepressant. J Psychosoc Nurs Ment Health Serv. 2022; 60(11): 9–11.
- Steinmiller CL, Maisonneuve IM, Glick SD. Effects of dextromethorphan on dopamine release in the nucleus accumbens: Interactions with morphine. Pharmacol Biochem Behav. 2003; 74(4): 803–810.
- Iosifescu DV, Jones A, O'Gorman C, et al. Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). J Clin Psychiatry. 2022; 83(4).
- Tabuteau H, Jones A, Anderson A, et al. Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022; 179(7): 490–499.
- Bem JL, Peck R. Dextromethorphan. An overview of safety issues. Drug Saf. 1992; 7(3): 190–199.
- Meisner JA, Wilcox SR, Richards JB. Ibogaine-associated cardiac arrest and death: case report and review of the literature. Ther Adv Psychopharmacol. 2016; 6(2): 95–98.
- Litjens RPW, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016; 54(4): 297–302.
- Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018; 44(1): 37–46.
- Jelen LA, Young AH, Stone JM. Ketamine: a tale of two enantiomers. J Psychopharmacol. 2021; 35(2): 109–123.
- Carrillo P, Petit AC, Gaillard R, et al. The next psychoactive drugs: from imipramine to ketamine. Bull Acad Natl Med. 2020; 204(9): e169–e177.
- Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018; 23(4): 801–811.
- Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018; 75(2): 139–148.
- Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019; 22(10): 616–630.
- Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016; 80(6): 424–431.
- Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology. 2020; 45(4): 606–612.
- Bernschneider-Reif S, Oxler F, Freudenmann RW. The origin of MDMA ("ecstasy") — separating the facts from the myth. Pharmazie. 2006; 61(11): 966–972.
- Passie T, Benzenhöfer U. The history of MDMA as an underground drug in the united states, 1960–1979. J Psychoactive Drugs. 2016; 48(2): 67–75.
- Underhill SM, Hullihen PD, Chen J, et al. Amphetamines signal through intracellular TAAR1 receptors coupled to Gα and Gα in discrete subcellular domains. Mol Psychiatry. 2021; 26(4): 1208–1223.
- Lizarraga LE, Cholanians AB, Phan AV, et al. Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine. Toxicol Sci. 2015; 143(1): 209–219.
- Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022; 87(4): 800–806.
- Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-Assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Focus (Am Psychiatr Publ). 2023; 21(3): 315–328.
- Nicholas CR, Wang JB, Coker A, et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 2022; 233: 109356.
- Brewerton TD, Lafrance A, Mithoefer MC. The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD. Med Hypotheses. 2021; 146: 110367.
- Chaliha D, Mamo JC, Albrecht M, et al. A systematic review of the MDMA model to address social impairment in autism. Curr Neuropharmacol. 2021; 19(7): 1101–1154.
- Danforth AL. Embracing neurodiversity in psychedelic science: a mixed-methods inquiry into the MDMA experiences of autistic adults. J Psychoactive Drugs. 2019; 51(2): 146–154.
- Psiuk D, Nowak E, Cholewa K, et al. The potential role of serotonergic hallucinogens in depression treatment. Life (Basel). 2021; 11(8).
- Jones GM, Nock MK. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. J Psychopharmacol. 2022; 36(1): 46–56.
- Burgess C, O'Donohoe A, Gill M. Agony and ecstasy: a review of MDMA effects and toxicity. Eur Psychiatry. 2000; 15(5): 287–294.
- Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021; 27(6): 1025–1033.
- Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020; 22(3): 223–228.
- Gilman JM, Schmitt WA, Potter K, et al. Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging. Neuropsychopharmacology. 2022; 47(4): 944–952.
- Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020; 16(1): 9–29.
- Mayo LM, Rabinak CA, Hill MN, et al. Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: a promising case of preclinical-clinical translation? Biol Psychiatry. 2022; 91(3): 262–272.
- Martin EL, Strickland JC, Schlienz NJ, et al. Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial. Front Psychiatry. 2021; 12: 729800.
- Zabik NL, Rabinak CA, Peters CA, et al. Cannabinoid modulation of corticolimbic activation during extinction learning and fear renewal in adults with posttraumatic stress disorder. Neurobiol Learn Mem. 2023; 201: 107758.
- Esketamine nasal spray for treatment‐resistant depression. Med Lett Drugs Ther. 2019; 61(1569): 54–57.
- Haridy R. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Nature. 2023; 619(7969): 227–228.
